Heron Therapeutics, Inc. · NASDAQ:HRTX
Heron Therapeutics — Investor Presentation (August 2016)
12 slides from Heron Therapeutics's investor presentation, Aug 10, 2016
Slide 1: Company Update
Company Update August 10, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation, and
Slide 3: SUSTOL: Now approved by U.S. FDA
SUSTOL® Now approved by U.S. FDA U.S. Commercial Launch Planned For Q4 2016 3
Slide 4: Preventing CINV throughout acute and delayed phases remains a significant unmet need
Preventing CINV throughout both acute and delayed phases remains a significant unmet need Patients identified CINV as the side effect of % of emetogenic chemotherapy patients with chemotherapy they most wanted to avoid breakthrough CINV despite prophylaxis Physician perception Least acceptable 50% 5
Slide 5: SUSTOL Indication
SUSTOL Indication SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy
Slide 6: AC-based regimens are classified as highly emetogenic by national clinical practice guidelines
AC-based regimens are classified as highly emetogenic by national clinical practice guidelines Highly Emetogenic Chemotherapy • AC combination chemotherapy* • Dacarbazine • Carmustine >250 mg/m2 • Doxorubicin >60 mg/m2 • Cisplatin • Epirubicin >90 mg/m2 NCCN • Cyclophosphamide >1,500 mg/m2 • Ifosfam
Slide 7: The branded 5-HT3 market (Aloxi) consists of ~2.5 million units
The branded 5-HT3 market (Aloxi) consists of ~2.5 million units Injectable 5-HT3 Receptor Antagonists for the Prevention of CINV Number of Vials Sold in the U.S. by Quarter 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 - Q1'13 Q2'13 Q3'13 Q4'13 Q1'14 Q2'14 Q3'14 Q4'14 Q1'15 Q2'15 Q
Slide 8: 93% of palonosetron units are used outside of cisplatin
93% of palonosetron units are used outside of cisplatin Total U.S. palonosetron Units (2015) 3.0 By Chemo Regimen 2.5 0.18 Units (Millions) 2.0 Cisplatin 1.5 Other Chemotherapy 2.35 1.0 0.5 0.0 Source: Intrinsiq 2013 (for Aloxi units); Symphony 2015 (for proportion of chemo that is cisplatin) 8
Slide 9: Our target market can be reached by a small but focused commercial team
Our target market can be reached by a small but focused commercial team Commercial launch to be highly-targeted with two key phases Phase 1 Targets Highly-concentrated • 700K branded units (50%) in 70 practices (533 sites) Phase 1 Targets Value clinical advances over 1st (First 12-18 months) gen
Slide 10: Heron's commercial plans will address potential launch barriers for providers, patients, and payers
Heron’s commercial plans will address potential launch barriers for providers, patients, and payers Objectives Action Plan • First and only 5-HT3 with advanced, extended-release technology Establish SUSTOL and 5-day CINV prevention in MEC and AC-based HEC regimens1 clinical value & • Robust in-offic
Slide 11: U.S. commercial organization is poised for launch
U.S. commercial organization is poised for launch U.S. Commercial Organization Marketing Sales Phase 1 Targets Market Access (First 12-18 months) ~1.4MM Units GPO Account Team Payer Account Team MSLs / Nurse Educators Source: Symphony SNR data 2015 11
Slide 12: SUSTOL Now Approved
SUSTOL Now Approved “Despite advances in the management of CINV, up to half of patients receiving chemotherapy can still experience CINV, with delayed CINV being particularly challenging to control,” commented Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders. “In ou
Heron Therapeutics — Investor Presentation (August 2016) on 6ix